MALVERN,
Pa., May 6, 2024 /CNW/ -- Endo, Inc. announced
today that its Endo Injectable Solutions business unit launched its
enhanced ready-to-use product line and platform,
TruDelivery®, underscoring the company's commitment to
building its ready-to-administer and ready-to-use portfolio.
"As the name suggests, TruDelivery delivers—without mixing,
compounding, or diluting—so our customers can focus on quality
patient care," said Scott Sims,
Senior Vice President and General Manager, Injectable Solutions
& Generics at Endo. "In addition to operational efficiencies,
ready-to-administer and ready-to-use products may help reduce the
risk of medication errors that can lead to unintended but
catastrophic outcomes."
The U.S. Food and Drug Administration (FDA) encourages the
manufacture of products specifically designed to minimize
medication errors. Even under the best circumstances, extra steps
in product preparation, including mixing, compounding, or transfer
to another container, may introduce the risk of error.
Sims continued, "We are committed to providing these important
medications to hospital pharmacies, and in fact, there are dozens
of ready-to-use projects in Endo's pipeline that will join our
current list of offerings over the next several years."
The TruDelivery website provides information about the
operational and safety benefits of RTU products and highlights
Endo's current ready-to-administer and ready-to-use products.
- Bivalirudin injection RTU bottles
- Dexmedetomidine HCl injection RTU bottles
- Ephedrine sulfate injection premixed vials
- PREVDUO® (neostigmine methylsulfate and
glycopyrrolate) injection prefilled syringes
- VASOSTRICT® (vasopressin injection, USP) RTU
bottles
Ready-to-use, or RTU, products streamline operations for
hospitals by eliminating the need to prepare or transfer the
product before patient administration. This may reduce waste and
costs, optimize convenience and workflow and reduce the chance for
preparation error—all of which support quality patient care.
About Endo
Endo is a diversified specialty
pharmaceutical company boldly transforming insights into
life-enhancing therapies. Our passionate team members collaborate
to develop and deliver these essential medicines. Together, we are
committed to helping everyone we serve live their best life. Learn
more at www.endo.com or connect with us on LinkedIn.
PREVDUO is a registered trademark of Slayback Pharma LLC.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements including, but not limited to, the statements by Mr.
Sims and any statements relating to Endo's ready-to-use product
line and platform, product portfolio, project pipeline, potential
waste and cost reduction, operational efficiencies and risk
reduction. Statements including words such as "believes,"
"expects," "anticipates," "intends," "estimates," "plan," "will,"
"may," "look forward," "intends," "guidance," "future," "potential"
or similar expressions are forward-looking statements. Because
these statements reflect Endo's current views, expectations and
beliefs concerning future events, they involve risks and
uncertainties, some of which Endo may not currently be able to
predict. Although Endo believes that these forward-looking
statements and other information are based upon reasonable
assumptions and expectations, readers should not place undue
reliance on these or any other forward-looking statements and
information. Actual results may differ materially and adversely
from current expectations based on a number of factors, including,
among other things, the following: the effects of the emergence of
Endo International plc's assets from the Chapter 11 financial
restructuring process, including as it relates to the accounting
for the effects of the Plan of Reorganization and the application
of fresh start accounting; changes in competitive, market or
regulatory conditions; changes in legislation or regulations; the
ability to obtain and maintain adequate protection for intellectual
property rights; the impacts of competition such as those related
to XIAFLEX®; the timing and uncertainty of the results of both the
research and development and regulatory processes; health care and
cost containment reforms, including government pricing, tax and
reimbursement policies; the performance including the approval,
introduction and consumer and physician acceptance of current and
new products; the ability to develop and expand our product
pipeline and to continue to develop the market for our branded or
unbranded products; the effectiveness of advertising and other
promotional campaigns; and the timely and successful implementation
of any strategic priorities. Endo assumes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise, except as may be
required under applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/endo-launches-enhanced-trudelivery-ready-to-use-product-line-and-platform-302136169.html
SOURCE Endo, Inc.